Form 4: Axsome Director Susan Mahony Sells Shares for Taxes

Director Susan Mahony converted 1,429 restricted stock units and sold 600 shares to satisfy tax obligations under a pre-arranged trading plan.

Summary

• Director Susan Mahony exercised 1,429 Restricted Stock Units (RSUs) on June 8, 2026, which converted to common stock on a one-for-one basis.
• The RSUs were originally granted on June 6, 2025, and vested fully on the one-year anniversary.
• Following the conversion, 600 shares were sold in two tranches on June 9 and June 10, 2026, to cover tax liabilities.
• The sales were executed at prices of $237.21 and $246.18 per share, respectively.
• After these transactions, the reporting person directly owns 829 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a routine compensation-related filing that does not indicate a change in fundamental business strategy or insider sentiment.

Positives

• Transactions were conducted under a Rule 10b5-1 trading plan, which provides a defense against accusations of insider trading.
• The director retains approximately 58% of the shares from the recently vested RSU grant.
• The stock was sold at significant price points above $230, indicating strong market valuation at the time of sale.

Negatives

• The reporting person's direct ownership decreased from 1,429 shares to 829 shares following the tax-related sales.

Risks

• The completion of the current 10b5-1 plan means any future insider sales will require the establishment of a new plan or occur during open trading windows, subject to different regulatory scrutiny.

Future Outlook

The reporting person has completed the transactions under the specific 10b5-1 plan mentioned. No further scheduled sales under this specific plan are indicated.

Management Comments

• These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are a standard administrative procedure in the biotechnology sector, allowing executives to manage the immediate tax impact of equity vesting without necessarily reflecting a negative outlook on the company's future.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is consistent with corporate governance best practices at other mid-to-large cap biotech firms like Neurocrine Biosciences or Biogen.
• The sale of roughly 42% of a vested grant for taxes is typical for high-net-worth individuals subject to top-tier federal and state income tax brackets.

Related Party Transactions

• The transactions involve the issuance of common stock to a Director as part of an established equity incentive plan.

Stakeholder Impact

• Shareholders should view this as a routine administrative matter with negligible impact on the company's capital structure or float.

Next Steps

• Monitor for future Form 4 filings from other executives to determine if there is a broader trend of selling at these price levels.

Key Dates

Recommendation

This filing represents standard insider compensation activity and does not provide new material information regarding the company's clinical pipeline or financial performance that would warrant a change in investment thesis.

Keywords

Axsome Therapeutics, AXSM, Insider Trading, Form 4, Restricted Stock Units, Rule 10b5-1, Susan Mahony, Biotechnology, Equity Compensation